P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES

• A. Mato,
• A. Danilov,
• M. R. Patel,
• M. Tees,
• I. Flinn,
• W. Ai,
• K. Patel,
• M. Wang,
• S. M. O’Brien,
• S. Nandakumar,
• M. Tan,
• E. Meredith,
• M. Gessner,
• S. Y. Kim,
• A. Wiestner,
• W. G. Wierda

Affiliations

A. Mato

1 Memorial Sloan Kettering Cancer Center, New York

A. Danilov

2 City of Hope National Medical Center, Duarte

M. R. Patel

3 Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota

M. Tees

4 Colorado Blood Cancer Institute, Denver

I. Flinn

5 Sarah Cannon Research Institute and Tennessee Oncology, Nashville

W. Ai

6 University of California San Francisco Medical Center, San Francisco

K. Patel

7 Swedish Cancer Institute, Seattle

M. Wang

8 MD Anderson Cancer Center, Houston

S. M. O’Brien

9 Chao Family Comprehensive Cancer Center, University of California, Irvine

S. Nandakumar

10 Nurix Therapeutics, Inc., San Francisco

M. Tan

10 Nurix Therapeutics, Inc., San Francisco

E. Meredith

10 Nurix Therapeutics, Inc., San Francisco

M. Gessner

10 Nurix Therapeutics, Inc., San Francisco

S. Y. Kim

10 Nurix Therapeutics, Inc., San Francisco

A. Wiestner

11 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States of America

W. G. Wierda

8 MD Anderson Cancer Center, Houston